Compare · CRON vs DFTX
CRON vs DFTX
Side-by-side comparison of Cronos Group Inc. (CRON) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRON and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.60B, about 3.9x CRON ($1.18B).
- DFTX has been more active in the news (8 items in the past 4 weeks vs 4 for CRON).
- CRON has more recent analyst coverage (11 ratings vs 8 for DFTX).
- Company
- Cronos Group Inc.
- Definium Therapeutics Inc.
- Price
- -
- -
- Market cap
- $1.18B
- $4.60B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 4
- 8
- Recent ratings
- 11
- 8
Cronos Group Inc.
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under two adult-use brands, COVE and Spinach. The company also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Latest CRON
- SEC Form 8-K filed by Cronos Group Inc.
- Cronos Completes Acquisition of CanAdelaar, Europe’s Largest Adult-Use Cannabis Company
- Fan-Favorite and Limited-Edition Spinach® Green Apple-Flavored Products are Returning for the Fall Season
- Cronos Group Inc. to Hold 2026 Third Quarter Earnings Conference Call on November 5, 2026
- Cronos Hosts 2026 Investor Day
- Cronos to Host 2026 Investor Day at its Cronos GrowCo Facility in Kingsville, Ontario
- Cronos Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Cronos’ brand Spinach® Expands its Best-Selling Lineups of Edibles and Vapes
- SEC Form 4 filed by Director Garnick Murray R
- SEC Form 4 filed by Director Rudyk James Daniel
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.